MAPT and Alzheimer disease: In addition to Aβ and Tau, other cargo has been identified in EVs released by CNS cells that participate in AD-associated pathologies such as synaptic impairment [57], inflammation [[58], [59], [60]], lysosomal dysfunction [61], BBB disruption [62,63], and insulin resistance [55,64].